Given the limitations of planar optical imaging of brain tumours and quantification of fluorescence intensity, instead of ZEGFR:03115-IR700, we initially used the radiolabelled conjugate 18F-AlF-NOTA-ZEGFR:03115 to assess the efficacy of the affibody molecule in targeting EGFR-positive tumours in the brain setting. The gene discussed is EGFR; the disease is neoplasm.